ID   P53_HUMAN      STANDARD;      PRT;   393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
AC   Q16810; Q16811; Q16848; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8;
AC   Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987 (Rel. 05, Created)
DT   01-MAR-1989 (Rel. 10, Last sequence update)
DT   13-SEP-2005 (Rel. 48, Last annotation update)
DE   Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53)
DE   (Antigen NY-CO-13).
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=85230577; PubMed=4006916;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=87064416; PubMed=2946935;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=85267676; PubMed=3894933;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=87089826; PubMed=3025664;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA   Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=89108008; PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA   Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the
RT   human p53 gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 101-393.
RX   MEDLINE=85126934; PubMed=6396087;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA   Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression
RT   of the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [7]
RP   NUCLEOTIDE SEQUENCE, VARIANTS BURKITT'S LYMPHOMA, AND VARIANT ARG-72.
RX   MEDLINE=92007731; PubMed=1915267;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
RX   MEDLINE=93303270; PubMed=8316628;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE, AND VARIANT ARG-72.
RX   MEDLINE=21264809; PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [10]
RP   NUCLEOTIDE SEQUENCE.
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE.
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE, AND VARIANTS SER-47; ARG-72; LYS-339 AND ALA-366.
RA   Livingston R.J., Rieder M.J., Chung M.-W., Ritchie T.K., Olson A.N.,
RA   Nguyen C.P., Gildersleeve H., Cassidy C.M., Johnson E.J.,
RA   Swanson J.E., McFarland I., Yool B., Park C., Nickerson D.A.;
RT   "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
RT   of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
RX   PubMed=11023613;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72; HIS-273 AND SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-72 AND
RP   ALA-278.
RC   TISSUE=Kidney;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [16]
RP   NUCLEOTIDE SEQUENCE OF 1-379, AND VARIANTS ARG-72 AND ASN-139.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [17]
RP   NUCLEOTIDE SEQUENCE OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism
RT   patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE OF 261-298.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated
RT   with cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE OF 262-306.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification
RT   of the p53 gene from microdissected tissue: application to archival
RT   tumor samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   NUCLEOTIDE SEQUENCE OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   RNA-BINDING.
RX   MEDLINE=91141509; PubMed=1705009;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
RT   linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [24]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=96197761; PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in
RT   normal cells.";
RL   Oncogene 12:813-818(1996).
RN   [25]
RP   NUCLEAR LOCALIZATION SIGNAL.
RX   MEDLINE=90191730; PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a
RT   p34cdc2 kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [26]
RP   MINIMAL REPRESSION DOMAIN.
RX   MEDLINE=21125692; PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression
RT   domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [27]
RP   INTERACTION WITH ING4.
RX   MEDLINE=22635239; PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [28]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   MEDLINE=90280456; PubMed=2141171;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [29]
RP   DEPHOSPHORYLATION BY PP2A.
RX   MEDLINE=91172186; PubMed=1848668;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT   by protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [30]
RP   O-GLYCOSYLATION.
RX   MEDLINE=96197773; PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [31]
RP   PHOSPHORYLATION BY PRPK.
RX   MEDLINE=21570176; PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J.-I., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase
RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT   tumor cell lines, and the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [32]
RP   PHOSPHORYLATION SITE THR-18.
RX   MEDLINE=20406546; PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [33]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   MEDLINE=21659718; PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [34]
RP   PHOSPHORYLATION SITE THR-55, MUTAGENESIS OF THR-55, AND INTERACTION
RP   WITH TAF1.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [35]
RP   ACETYLATION SITE LYS-305.
RX   MEDLINE=22726738; PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [36]
RP   ACETYLATION SITES LYS-373 AND LYS-382.
RX   MEDLINE=20123976; PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to
RT   ionizing radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [37]
RP   DEACETYLATION OF LYS-382 BY SIRT1.
RX   MEDLINE=21526627; PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S.-I., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [38]
RP   INTERACTION WITH HIPK2.
RX   MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [39]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION SITE SER-46, AND MUTAGENESIS
RP   OF SER-46 AND LYS-382.
RX   MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [40]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION SITE SER-46.
RX   MEDLINE=21638694; PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA   Fanciulli M., Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT   and mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [41]
RP   INTERACTION WITH P53DINP1.
RX   MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [42]
RP   INTERACTION WITH HIPK1.
RX   MEDLINE=22608637; PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [43]
RP   INTERACTIONS WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [44]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   MEDLINE=22825602; PubMed=12944468;
RX   DOI=10.1128/MCB.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [45]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   MEDLINE=21438235; PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [46]
RP   STRUCTURE BY NMR OF 319-360.
RX   MEDLINE=94294808; PubMed=8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [47]
RP   STRUCTURE BY NMR OF 325-355.
RX   MEDLINE=95292092; PubMed=7773777;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of
RT   p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [48]
RP   STRUCTURE BY NMR OF 326-354.
RX   MEDLINE=98026899; PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   MEDLINE=94294806; PubMed=8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
RT   understanding tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   MEDLINE=95184011; PubMed=7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   MEDLINE=97081050; PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   MEDLINE=97035414; PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [53]
RP   REVIEW.
RX   MEDLINE=94090335; PubMed=8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk
RT   assessment.";
RL   Science 262:1980-1981(1993).
RN   [54]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=91289156; PubMed=1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [55]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=96271983; PubMed=8829653;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes
RT   designed to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [56]
RP   VARIANT ARG-72.
RX   MEDLINE=91153807; PubMed=1999338; DOI=10.1007/BF00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of
RT   the Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [57]
RP   VARIANT LFS THR-133.
RX   MEDLINE=92034774; PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [58]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   MEDLINE=91057657; PubMed=1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA   Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
RT   sarcomas, and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [59]
RP   VARIANT LFS ASP-245.
RX   MEDLINE=91080929; PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT   with Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [60]
RP   VARIANT LFS LEU-272.
RX   MEDLINE=92147883; PubMed=1737852;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA   Knutsen T., Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [61]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   MEDLINE=92228023; PubMed=1565144;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA   Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and
RT   young adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [62]
RP   VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   MEDLINE=90295284; PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast
RT   cancer cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [63]
RP   VARIANTS COLON TUMORS PHE-241 AND HIS-273.
RX   MEDLINE=91017544; PubMed=1699228;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [64]
RP   VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND
RP   SER-278.
RX   MEDLINE=91088630; PubMed=2263646;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [65]
RP   VARIANTS COLORECTAL CANCER MUTATIONS.
RX   MEDLINE=91282784; PubMed=1647768;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [66]
RP   VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP   HIS-273.
RX   MEDLINE=91330175; PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA   Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [67]
RP   VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA.
RX   MEDLINE=91187113; PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular
RT   carcinomas.";
RL   Nature 350:427-428(1991).
RN   [68]
RP   VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA.
RX   MEDLINE=91187114; PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT   from southern Africa.";
RL   Nature 350:429-431(1991).
RN   [69]
RP   VARIANTS HNSCC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
RX   MEDLINE=93007999; PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [70]
RP   VARIANTS ANOGENITAL CARCINOMAS.
RX   MEDLINE=93010989; PubMed=1327751;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary
RT   cervical cancers suggest mechanisms of metastasis and involvement of
RT   environmental carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [71]
RP   VARIANTS ORAL SQUAMOUS CELL CARCINOMA CYS-205; GLU-281 AND LYS-285.
RX   MEDLINE=93093790; PubMed=1459726;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [72]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   MEDLINE=93265016; PubMed=1303181;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [73]
RP   VARIANTS BURKITT'S LYMPHOMAS.
RX   MEDLINE=93064692; PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization
RT   relative to other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [74]
RP   VARIANT NASOPHARYNGEAL CARCINOMA THR-280.
RX   MEDLINE=92335329; PubMed=1631151;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Cao Y.,
RA   Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [75]
RP   VARIANTS HNSCC.
RX   MEDLINE=93235942; PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [76]
RP   VARIANTS HNSCC.
RX   MEDLINE=94006220; PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and
RT   neck cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [77]
RP   VARIANTS COLON TUMORS.
RX   MEDLINE=93330562; PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [78]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   MEDLINE=94283378; PubMed=8013454;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [79]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   MEDLINE=95193787; PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [80]
RP   VARIANT LFS HIS-175.
RX   MEDLINE=96423319; PubMed=8825920;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA   Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT   175 mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [81]
RP   VARIANTS ESOPHAGEAL ADENOCARCINOMA PHE-176; SER-245; TRP-248; TRP-282
RP   AND GLN-286.
RX   MEDLINE=96233927; PubMed=8829627;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [82]
RP   VARIANTS COLORECTAL TUMORS.
RX   MEDLINE=97255965; PubMed=9101296;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
RT   to genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [83]
RP   VARIANT COLORECTAL CARCINOMA ILE-157.
RX   MEDLINE=98080146; PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [84]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP   AND SER-278.
RX   MEDLINE=98111377; PubMed=9450901;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [85]
RP   VARIANT NONCLASSICAL LFS CYS-337.
RX   MEDLINE=98112421; PubMed=9452042;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [86]
RP   VARIANT LFS ILE-292.
RX   MEDLINE=99414637; PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT   a Li-Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [87]
RP   INVOLVEMENT IN CHOROID PLEXUS PAPILLOMA.
RX   MEDLINE=22079076; PubMed=12085209; DOI=10.1038/sj/bjc/6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel
RT   germline p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
CC       consisiting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
CC       a homotetramer. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. In vitro, the interaction of TP53 with cancer-
CC       associated/HPV (E6) viral proteins leads to ubiquitination and
CC       degradation of TP53 giving a possible model for cell growth
CC       regulation. This complex formation requires an additional factor,
CC       E6-AP, which stably associates with TP53 in the presence of E6. C-
CC       terminus interacts with TAF1, when TAF1 is part of the TFIID
CC       complex. Interacts with ING4 and this interaction may be indirect.
CC       Found in a complex with CABLES1 and TP73. Interacts with HIPK1,
CC       HIPK2, and P53DINP1.
CC   -!- INTERACTION:
CC       Q8TDN4:CABLES1; NbExp=1; IntAct=EBI-366083, EBI-604615;
CC       Q9ESJ1:Cables1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-604411;
CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-366083, EBI-81215;
CC       P42858:HD; NbExp=2; IntAct=EBI-366083, EBI-466029;
CC       P09429:HMGB1; NbExp=1; IntAct=EBI-366083, EBI-389432;
CC       P56273:MDM2 (xeno); NbExp=1; IntAct=EBI-366083, EBI-541233;
CC       Q00987:MDM2; NbExp=1; IntAct=EBI-366083, EBI-389668;
CC       P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579;
CC       P06748-1:NPM1; NbExp=1; IntAct=EBI-366083, EBI-354150;
CC       Q06609:RAD51; NbExp=1; IntAct=EBI-366083, EBI-297202;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       P20226:TBP; NbExp=1; IntAct=EBI-366083, EBI-355371;
CC       Q7Z6Z7:UREB1; NbExp=2; IntAct=EBI-366083, EBI-625934;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC         Note=Seems to be non-functional. Expressed in quiescent
CC         lymphocytes;
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
CC       repression domain.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
CC       impairs its ability to induce proapoptotic program and modulate
CC       cell senescence.
CC   -!- PTM: Phosphorylated. Phosphorylation on Ser residues mediates
CC       transcriptional activation. Phosphorylated by HIPK1 (By
CC       similarity). Phosphorylated on Thr-18 by VRK1, which may prevent
CC       the interaction with MDM2. Phosphorylated on Thr-55 by TAF1, which
CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by
CC       HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required
CC       for acetylation by CREBBP.
CC   -!- PTM: Dephosphorylated by PP2A. SV40 small T antigen inhibits the
CC       dephosphorylation by the AC form of PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
CC       in EB-1 cell line.
CC   -!- DISEASE: TP53 is found in increased amounts in a wide variety of
CC       transformed cells. TP53 is frequently mutated or inactivated in
CC       about 60% of cancers.
CC   -!- DISEASE: Defects in TP53 are involved in esophageal squamous cell
CC       carcinoma (ESCC) [MIM:133239]. ESCC is a tumor of the esophagus.
CC   -!- DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS)
CC       [MIM:151623]. LFS is an autosomal dominant familial cancer
CC       syndrome that in its classic form is defined by the existence of
CC       both a proband with a sarcoma and two other first-degree relatives
CC       with a cancer by age 45 years. In these families the affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. The spectrum of cancers in LFS includes breast carcinomas,
CC       soft-tissue sarcomas, brain tumors, osteosarcoma, leukemia and
CC       adreno-cortical carcinoma. Other possible component tumors of LFS
CC       are melanoma, gonadal cell tumors and carcinomas of the lung,
CC       pancreas and prostate.
CC   -!- DISEASE: Defects in TP53 are found in Barrett metaplasia; also
CC       known as Barrett esophagus. It is a condition in which the
CC       normally stratified squamous epithelium of the lower esophagus is
CC       replaced by a metaplastic columnar epithelium. The condition
CC       develops as a complication in approximately 10% of patients with
CC       chronic gastroesophageal reflux disease and predisposes to the
CC       development of esophageal adenocarcinoma.
CC   -!- DISEASE: Defects in TP53 are involved in head and neck squamous
CC       cell carcinomas (HNSCC) [MIM:275355].
CC   -!- DISEASE: Defects in TP53 are involved in oral squamous cell
CC       carcinoma (OSCC). Cigarette smoke is a prime mutagenic agent in
CC       cancer of the aerodigestive tract.
CC   -!- DISEASE: Defects in TP53 are a cause of lung cancer [MIM:211980].
CC   -!- DISEASE: Defects in TP53 are a cause of choroid plexus papilloma
CC       [MIM:260500]. Choroid plexus papilloma is a slow-growing benign
CC       tumor of the choroid plexus that often invades the leptomeninges.
CC       In children it is usually in a lateral ventricle but in adults it
CC       is more often in the fourth ventricle. Hydrocephalus is common,
CC       either from obstruction or from tumor secretion of cerebrospinal
CC       fluid. If it undergoes malignant transformation it is called a
CC       choroid plexus carcinoma. Primary choroid plexus tumors are rare
CC       and usually occur in early childhood.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -!- DATABASE: NAME=IARC TP53 mutation database;
CC       NOTE=IARC db of somatic p53 mutations;
CC       WWW="http://www.iarc.fr/p53/".
CC   -!- DATABASE: NAME=Tokyo p53;
CC       NOTE=University of Tokyo db of p53 mutations;
CC       WWW="http://p53.genome.ad.jp/".
CC   -!- DATABASE: NAME=p53 web site at the Institut Curie;
CC       WWW="http://p53.curie.fr/".
CC   -!- DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;
CC       WWW="http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html".
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   PIR; A25224; DNHU53.
DR   PDB; 1A1U; NMR; A/C=324-358.
DR   PDB; 1AIE; X-ray; @=326-356.
DR   PDB; 1C26; X-ray; A=325-356.
DR   PDB; 1DT7; NMR; X/Y=367-388.
DR   PDB; 1GZH; X-ray; A/C=-.
DR   PDB; 1H26; X-ray; E=376-386.
DR   PDB; 1HS5; NMR; A/B=324-357.
DR   PDB; 1KZY; X-ray; A/B=95-289.
DR   PDB; 1OLG; NMR; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; A/B/C/D=319-360.
DR   PDB; 1SAG; NMR; A/B/C/D=319-360.
DR   PDB; 1SAH; NMR; A/B/C/D=319-360.
DR   PDB; 1SAI; NMR; A/B/C/D=319-360.
DR   PDB; 1SAJ; NMR; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; A/B=94-312.
DR   PDB; 1YCQ; X-ray; B=13-29.
DR   PDB; 1YCR; X-ray; B=15-29.
DR   PDB; 1YCS; X-ray; A=94-292.
DR   PDB; 2BIM; X-ray; A/B=94-312.
DR   PDB; 2BIN; X-ray; A=94-312.
DR   PDB; 2BIO; X-ray; A=94-312.
DR   PDB; 2BIP; X-ray; A=94-312.
DR   PDB; 2BIQ; X-ray; A=94-312.
DR   PDB; 3SAK; NMR; A/B/C/D=319-360.
DR   IntAct; P04637; -.
DR   TRANSFAC; T00671; -.
DR   SWISS-2DPAGE; P04637; HUMAN.
DR   Ensembl; ENSG00000141510; Homo sapiens.
DR   HGNC; HGNC:11998; TP53.
DR   H-InvDB; HIX0013510; -.
DR   Reactome; P04637; -.
DR   MIM; 191170; -.
DR   MIM; 133239; -.
DR   MIM; 151623; -.
DR   MIM; 275355; -.
DR   MIM; 211980; -.
DR   MIM; 260500; -.
DR   GO; GO:0005739; C:mitochondrion; IDA.
DR   GO; GO:0005730; C:nucleolus; IDA.
DR   GO; GO:0005524; F:ATP binding; IDA.
DR   GO; GO:0005507; F:copper ion binding; IDA.
DR   GO; GO:0000739; F:DNA strand annealing activity; IDA.
DR   GO; GO:0004518; F:nuclease activity; TAS.
DR   GO; GO:0005515; F:protein binding; IPI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI.
DR   GO; GO:0003700; F:transcription factor activity; IDA.
DR   GO; GO:0008270; F:zinc ion binding; TAS.
DR   GO; GO:0006915; P:apoptosis; IDA.
DR   GO; GO:0006284; P:base-excision repair; TAS.
DR   GO; GO:0008635; P:caspase activation via cytochrome c; IDA.
DR   GO; GO:0007569; P:cell aging; IMP.
DR   GO; GO:0007050; P:cell cycle arrest; TAS.
DR   GO; GO:0000075; P:cell cycle checkpoint; TAS.
DR   GO; GO:0030154; P:cell differentiation; TAS.
DR   GO; GO:0008283; P:cell proliferation; TAS.
DR   GO; GO:0008630; P:DNA damage response, signal transduction re...; TAS.
DR   GO; GO:0006310; P:DNA recombination; TAS.
DR   GO; GO:0008628; P:induction of apoptosis by hormones; TAS.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP.
DR   GO; GO:0051262; P:protein tetramerization; TAS.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permea...; TAS.
DR   GO; GO:0006355; P:regulation of transcription, DNA-dependent; IDA.
DR   InterPro; IPR002117; P53.
DR   InterPro; IPR011615; P53_DNA_bd.
DR   InterPro; IPR012346; P53_RUNT_DNA_bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   ProDom; PD002681; P53; 1.
DR   PROSITE; PS00348; P53; 1.
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Anti-oncogene; Apoptosis; Cell cycle; Disease mutation; DNA-binding;
KW   Glycoprotein; Li-Fraumeni syndrome; Metal-binding; Nuclear protein;
KW   Phosphorylation; Polymorphism; Transcription;
KW   Transcription regulation; Zinc.
FT   DNA_BIND    102    292
FT   REGION        1     83       Interaction with HRMT1L2.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION      100    370       Interaction with HIPK1 (By similarity).
FT   REGION      116    292       Interaction with AXIN1 (By similarity).
FT   REGION      241    248       Interacts with the 53BP2 SH3 domain.
FT   REGION      300    393       Interaction with CARM1.
FT   REGION      319    360       Interaction with HIPK2.
FT   REGION      325    356       Oligomerization.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT   MOTIF       339    350       Nuclear export signal.
FT   METAL       176    176       Zinc.
FT   METAL       179    179       Zinc.
FT   METAL       238    238       Zinc.
FT   METAL       242    242       Zinc.
FT   BINDING     392    392       5'-phospho-RNA (covalent).
FT   MOD_RES      15     15       Phosphoserine (by PRPK).
FT   MOD_RES      18     18       Phosphothreonine (by VRK1).
FT   MOD_RES      46     46       Phosphoserine (by HIPK2).
FT   MOD_RES      55     55       Phosphothreonine (by TAF1).
FT   MOD_RES     305    305       N6-acetyllysine.
FT   MOD_RES     315    315       Phosphoserine (by CDC2).
FT   MOD_RES     373    373       N6-acetyllysine.
FT   MOD_RES     382    382       N6-acetyllysine.
FT   VARSPLIC    332    341       IRGRERFEMF -> DGTSFQKENC (in isoform 2).
FT                                /FTId=VSP_006535.
FT   VARSPLIC    342    393       Missing (in isoform 2).
FT                                /FTId=VSP_006536.
FT   VARIANT       7      7       D -> H (in a skin tumor).
FT                                /FTId=VAR_005851.
FT   VARIANT      35     35       L -> F (in a liver tumor).
FT                                /FTId=VAR_005852.
FT   VARIANT      43     43       L -> S (in a renal tumor).
FT                                /FTId=VAR_005853.
FT   VARIANT      47     47       P -> S (in dbSNP:1800371).
FT                                /FTId=VAR_014632.
FT   VARIANT      53     53       W -> C (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005854.
FT   VARIANT      60     60       P -> S (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005855.
FT   VARIANT      72     72       P -> R (in dbSNP:1042522).
FT                                /FTId=VAR_005856.
FT   VARIANT      79     79       A -> T (in clone P53-H-1).
FT                                /FTId=VAR_005857.
FT   VARIANT      87     87       P -> Q (in a brain tumor).
FT                                /FTId=VAR_005858.
FT   VARIANT      94     94       S -> T (in a colon tumor).
FT                                /FTId=VAR_005859.
FT   VARIANT     110    110       R -> C (in a liver and an uterus tumor).
FT                                /FTId=VAR_005860.
FT   VARIANT     110    110       R -> L (in a liver tumor).
FT                                /FTId=VAR_005861.
FT   VARIANT     110    110       R -> P (in a breast tumor).
FT                                /FTId=VAR_005862.
FT   VARIANT     113    113       F -> C (in a lung tumor).
FT                                /FTId=VAR_005863.
FT   VARIANT     125    125       T -> M (in a lung tumor).
FT                                /FTId=VAR_005864.
FT   VARIANT     126    126       Y -> D (in a colorectal tumor).
FT                                /FTId=VAR_005865.
FT   VARIANT     126    126       Y -> N (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005866.
FT   VARIANT     127    127       S -> F (in a lung tumor).
FT                                /FTId=VAR_005867.
FT   VARIANT     128    128       P -> S (in a breast tumor).
FT                                /FTId=VAR_005868.
FT   VARIANT     129    129       A -> D (in a sarcoma).
FT                                /FTId=VAR_005869.
FT   VARIANT     130    130       L -> R (in a liver tumor).
FT                                /FTId=VAR_005870.
FT   VARIANT     131    131       N -> K (in a colon tumor).
FT                                /FTId=VAR_005872.
FT   VARIANT     131    131       N -> S (in a liver tumor).
FT                                /FTId=VAR_005871.
FT   VARIANT     132    132       K -> M (in a sarcoma).
FT                                /FTId=VAR_005873.
FT   VARIANT     132    132       K -> Q (in a breast tumor).
FT                                /FTId=VAR_005874.
FT   VARIANT     133    133       M -> T (in LFS).
FT                                /FTId=VAR_005875.
FT   VARIANT     135    135       C -> F (in a colon tumor).
FT                                /FTId=VAR_005877.
FT   VARIANT     135    135       C -> S (in a colon tumor).
FT                                /FTId=VAR_005876.
FT   VARIANT     136    136       Q -> E (in a breast tumor).
FT                                /FTId=VAR_005878.
FT   VARIANT     136    136       Q -> K (in a colon tumor).
FT                                /FTId=VAR_005879.
FT   VARIANT     137    137       L -> Q (in a liver tumor).
FT                                /FTId=VAR_005880.
FT   VARIANT     138    138       A -> P (in a lung tumor).
FT                                /FTId=VAR_005881.
FT   VARIANT     139    139       K -> N (in a breast, an ovary tumor, a
FT                                leukemia and a lymphoma).
FT                                /FTId=VAR_005882.
FT   VARIANT     140    140       T -> Y (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005883.
FT   VARIANT     141    141       C -> F (in a breast tumor).
FT                                /FTId=VAR_005885.
FT   VARIANT     141    141       C -> G (in an ovary tumor).
FT                                /FTId=VAR_005884.
FT   VARIANT     141    141       C -> Y (in many types of tumors).
FT                                /FTId=VAR_005886.
FT   VARIANT     143    143       V -> A (in a colon tumor; strong DNA
FT                                binding ability at 32.5 degrees Celsius;
FT                                strong reduction of transcriptional
FT                                activity at 37.5 degrees Celsius).
FT                                /FTId=VAR_005887.
FT   VARIANT     144    144       Q -> P (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005888.
FT   VARIANT     145    145       L -> P (in a brain tumor).
FT                                /FTId=VAR_005889.
FT   VARIANT     145    145       L -> Q (in an esophagus tumor).
FT                                /FTId=VAR_005890.
FT   VARIANT     147    147       V -> D (in an ovary tumor).
FT                                /FTId=VAR_005891.
FT   VARIANT     147    147       V -> G (in a prostate tumor).
FT                                /FTId=VAR_005892.
FT   VARIANT     149    149       S -> P (in a breast tumor).
FT                                /FTId=VAR_005893.
FT   VARIANT     151    151       P -> A (in a brain and a colon tumor).
FT                                /FTId=VAR_005894.
FT   VARIANT     151    151       P -> S (in many types of tumors).
FT                                /FTId=VAR_005895.
FT   VARIANT     151    151       P -> T (in a breast tumor).
FT                                /FTId=VAR_005896.
FT   VARIANT     152    152       P -> L (in an esophagus tumor).
FT                                /FTId=VAR_005897.
FT   VARIANT     152    152       P -> S (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005898.
FT   VARIANT     153    153       P -> T (in a colon tumor).
FT                                /FTId=VAR_005899.
FT   VARIANT     154    154       G -> V (in esophagus tumor).
FT                                /FTId=VAR_005900.
FT   VARIANT     155    155       T -> A (in an esophagus tumor).
FT                                /FTId=VAR_005901.
FT   VARIANT     156    156       R -> P (in an osteosarcoma cell line).
FT                                /FTId=VAR_005902.
FT   VARIANT     157    157       V -> D (in a liver tumor).
FT                                /FTId=VAR_005903.
FT   VARIANT     157    157       V -> I (in colorectal carcinoma; from a
FT                                patient with Turcot syndrome).
FT                                /FTId=VAR_012977.
FT   VARIANT     157    157       V -> S (in a S. African hepatocellular
FT                                carcinoma).
FT                                /FTId=VAR_005904.
FT   VARIANT     158    158       R -> C (in a noninvasive head and neck
FT                                tumor).
FT                                /FTId=VAR_005905.
FT   VARIANT     158    158       R -> G (in a brain and a lung tumor).
FT                                /FTId=VAR_005906.
FT   VARIANT     158    158       R -> H (in many types of tumors).
FT                                /FTId=VAR_005907.
FT   VARIANT     160    160       M -> I (in a lung and a skin tumor).
FT                                /FTId=VAR_005908.
FT   VARIANT     161    161       A -> S (in a brain tumor).
FT                                /FTId=VAR_005909.
FT   VARIANT     162    162       I -> S (in a brain tumor).
FT                                /FTId=VAR_005910.
FT   VARIANT     162    162       I -> V (in an ovary tumor).
FT                                /FTId=VAR_005911.
FT   VARIANT     163    163       Y -> H (in HNSCC).
FT                                /FTId=VAR_005912.
FT   VARIANT     164    164       K -> N (in a lung tumor).
FT                                /FTId=VAR_005913.
FT   VARIANT     164    164       K -> Q (in a breast tumor).
FT                                /FTId=VAR_005914.
FT   VARIANT     165    165       Q -> L (in a breast tumor).
FT                                /FTId=VAR_005915.
FT   VARIANT     165    165       Q -> R (in an ovary tumor).
FT                                /FTId=VAR_005916.
FT   VARIANT     166    166       S -> L (in a lung tumor).
FT                                /FTId=VAR_005917.
FT   VARIANT     168    168       H -> R (in a brain tumor).
FT                                /FTId=VAR_005918.
FT   VARIANT     169    169       M -> I (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005919.
FT   VARIANT     169    169       M -> T (in a noninvasive head and neck
FT                                tumor).
FT                                /FTId=VAR_005920.
FT   VARIANT     170    170       T -> M (in a colon tumor).
FT                                /FTId=VAR_005921.
FT   VARIANT     170    170       T -> S (in a colon tumor).
FT                                /FTId=VAR_005922.
FT   VARIANT     172    172       V -> A (in a prostate tumor).
FT                                /FTId=VAR_005923.
FT   VARIANT     173    173       V -> E (in a colon tumor).
FT                                /FTId=VAR_005924.
FT   VARIANT     173    173       V -> L (in a cervical carcinoma).
FT                                /FTId=VAR_005925.
FT   VARIANT     173    173       V -> M (in a colon tumor).
FT                                /FTId=VAR_005926.
FT   VARIANT     174    174       R -> H (in the cell line Detroit 562 of
FT                                squamous cell carcinoma).
FT                                /FTId=VAR_005927.
FT   VARIANT     175    175       R -> C (in a colon and an uterus tumor).
FT                                /FTId=VAR_005928.
FT   VARIANT     175    175       R -> G (in a brain tumor).
FT                                /FTId=VAR_005929.
FT   VARIANT     175    175       R -> H (in LFS and colon/esophagus/
FT                                gastric tumors).
FT                                /FTId=VAR_005932.
FT   VARIANT     175    175       R -> L (in a breast and a colon tumor).
FT                                /FTId=VAR_005930.
FT   VARIANT     175    175       R -> P (in a cervical carcinoma).
FT                                /FTId=VAR_005931.
FT   VARIANT     176    176       C -> F (in esophagus tumors and many
FT                                types of tumors).
FT                                /FTId=VAR_005933.
FT   VARIANT     176    176       C -> W (in a lung tumor).
FT                                /FTId=VAR_005934.
FT   VARIANT     177    177       P -> L (in a skin tumor).
FT                                /FTId=VAR_005935.
FT   VARIANT     178    178       H -> HPHP (in a Burkitt's lymphoma).
FT                                /FTId=VAR_005936.
FT   VARIANT     181    181       R -> L (in a cervical carcinoma).
FT                                /FTId=VAR_005937.
FT   VARIANT     182    182       C -> S (in a stomach tumor).
FT                                /FTId=VAR_005938.
FT   VARIANT     184    184       D -> Y (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005939.
FT   VARIANT     186    186       D -> Y (in a breast tumor).
FT                                /FTId=VAR_005940.
FT   VARIANT     187    187       G -> C (in a breast tumor).
FT                                /FTId=VAR_005941.
FT   VARIANT     187    187       G -> S (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005942.
FT   VARIANT     189    189       A -> P (in an ovary tumor).
FT                                /FTId=VAR_005943.
FT   VARIANT     190    190       P -> L (in a colorectal tumor).
FT                                /FTId=VAR_005944.
FT   VARIANT     191    191       P -> T (in a colon tumor).
FT                                /FTId=VAR_005945.
FT   VARIANT     192    192       Q -> R (in a colon tumor).
FT                                /FTId=VAR_005946.
FT   VARIANT     193    193       H -> D (in an uterus tumor).
FT                                /FTId=VAR_005947.
FT   VARIANT     193    193       H -> R (in LFS).
FT                                /FTId=VAR_005948.
FT   VARIANT     194    194       L -> P (in a colon tumor).
FT                                /FTId=VAR_005949.
FT   VARIANT     194    194       L -> R (in the cell line HU 281 of
FT                                squamous cell carcinoma).
FT                                /FTId=VAR_005950.
FT   VARIANT     195    195       I -> T (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005951.
FT   VARIANT     198    198       E -> K (in HNSCC).
FT                                /FTId=VAR_005952.
FT   VARIANT     205    205       Y -> C (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005953.
FT   VARIANT     205    205       Y -> D (in HNSCC).
FT                                /FTId=VAR_005954.
FT   VARIANT     213    213       R -> Q (in a Burkitt's lymphoma and a
FT                                colorectal tumor).
FT                                /FTId=VAR_005955.
FT   VARIANT     216    216       V -> M (in HNSCC).
FT                                /FTId=VAR_005956.
FT   VARIANT     220    220       Y -> C (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005957.
FT   VARIANT     220    220       Y -> H (in a colon tumor).
FT                                /FTId=VAR_005958.
FT   VARIANT     220    220       Y -> S (in HNSCC).
FT                                /FTId=VAR_005959.
FT   VARIANT     228    228       D -> E (in HNSCC).
FT                                /FTId=VAR_005960.
FT   VARIANT     230    230       T -> I (in oral squamous cell carcinoma).
FT                                /FTId=VAR_005961.
FT   VARIANT     232    232       I -> T (in an anal tumor).
FT                                /FTId=VAR_005962.
FT   VARIANT     234    234       Y -> C (in HNSCC).
FT                                /FTId=VAR_005963.
FT   VARIANT     234    234       Y -> H (in a Burkitt's lymphoma).
FT                                /FTId=VAR_005964.
FT   VARIANT     237    237       M -> I (in a colon tumor).
FT                                /FTId=VAR_005965.
FT   VARIANT     238    238       C -> F (in an anal tumor).
FT                                /FTId=VAR_005966.
FT   VARIANT     238    238       C -> Y (in a colorectal tumor).
FT                                /FTId=VAR_005967.
FT   VARIANT     240    240       S -> I (in an anal tumor).
FT                                /FTId=VAR_005968.
FT   VARIANT     241    241       S -> F (in a colon tumor).
FT                                /FTId=VAR_005969.
FT   VARIANT     242    242       C -> F (in a skin tumor).
FT                                /FTId=VAR_005970.
FT   VARIANT     245    245       G -> A (in a renal tumor).
FT                                /FTId=VAR_005971.
FT   VARIANT     245    245       G -> C (in LFS, colon and larynx tumors).
FT                                /FTId=VAR_005972.
FT   VARIANT     245    245       G -> D (in LFS and a colon tumor).
FT                                /FTId=VAR_005973.
FT   VARIANT     245    245       G -> S (in esophageal adenocarcinoma and
FT                                many types of tumors).
FT                                /FTId=VAR_005974.
FT   VARIANT     245    245       G -> V (in HNSCC).
FT                                /FTId=VAR_005975.
FT   VARIANT     246    246       M -> R (in a liver tumor).
FT                                /FTId=VAR_005976.
FT   VARIANT     246    246       M -> T (in a leukemia and a lymphoma).
FT                                /FTId=VAR_005977.
FT   VARIANT     246    246       M -> V (in many types of tumors).
FT                                /FTId=VAR_005978.
FT   VARIANT     247    247       N -> I (in a lung tumor).
FT                                /FTId=VAR_005980.
FT   VARIANT     247    247       N -> W (in a skin tumor).
FT                                /FTId=VAR_005979.
FT   VARIANT     248    248       R -> G (in an endocrine tumor).
FT                                /FTId=VAR_005981.
FT   VARIANT     248    248       R -> L (in tumors of hypopharynx, larynx
FT                                and tonsil).
FT                                /FTId=VAR_005982.
FT   VARIANT     248    248       R -> Q (in LFS and many types of tumors).
FT                                /FTId=VAR_005983.
FT   VARIANT     248    248       R -> W (in LFS, esophageal adenocarcinoma
FT                                and many types of tumors).
FT                                /FTId=VAR_005984.
FT   VARIANT     249    249       R -> G (in a breast tumor).
FT                                /FTId=VAR_005985.
FT   VARIANT     249    249       R -> S (in many types of tumors).
FT                                /FTId=VAR_005986.
FT   VARIANT     251    251       I -> N (in HNSCC).
FT                                /FTId=VAR_005987.
FT   VARIANT     252    252       L -> P (in LFS and many types of tumors).
FT                                /FTId=VAR_005988.
FT   VARIANT     254    254       I -> N (in a breast tumor).
FT                                /FTId=VAR_017908.
FT   VARIANT     254    254       I -> T (in a colon tumor).
FT                                /FTId=VAR_017909.
FT   VARIANT     257    257       L -> P (in HNSCC).
FT                                /FTId=VAR_005989.
FT   VARIANT     258    258       E -> D (in a colorectal tumor).
FT                                /FTId=VAR_005990.
FT   VARIANT     258    258       E -> K (in LFS).
FT                                /FTId=VAR_005991.
FT   VARIANT     272    272       V -> L (in LFS).
FT                                /FTId=VAR_005992.
FT   VARIANT     273    273       R -> C (in LFS, colorectal tumor and oral
FT                                squamous cell carcinoma).
FT                                /FTId=VAR_005993.
FT   VARIANT     273    273       R -> G (in HNSCC).
FT                                /FTId=VAR_005994.
FT   VARIANT     273    273       R -> H (in LFS, colon and esophagus
FT                                tumors).
FT                                /FTId=VAR_005995.
FT   VARIANT     274    274       V -> F (in a colorectal tumor).
FT                                /FTId=VAR_005997.
FT   VARIANT     275    275       C -> W (in a breast and a stomach tumor).
FT                                /FTId=VAR_005999.
FT   VARIANT     275    275       C -> Y (in LFS and tumors of brain, lung,
FT                                kidney, stomach).
FT                                /FTId=VAR_005998.
FT   VARIANT     277    277       C -> G (in a lung tumor).
FT                                /FTId=VAR_006000.
FT   VARIANT     278    278       P -> A (in a breast tumor).
FT                                /FTId=VAR_006001.
FT   VARIANT     278    278       P -> H (in a leukemia and a lymphoma).
FT                                /FTId=VAR_006002.
FT   VARIANT     278    278       P -> L (in an esophagus and a lung
FT                                tumor).
FT                                /FTId=VAR_006003.
FT   VARIANT     278    278       P -> S (in oral squamous cell carcinoma).
FT                                /FTId=VAR_006004.
FT   VARIANT     278    278       P -> T (in HNSCC; same patient as
FT                                mutation His-281).
FT                                /FTId=VAR_006005.
FT   VARIANT     279    279       G -> E (in a colorectal tumor).
FT                                /FTId=VAR_006006.
FT   VARIANT     280    280       R -> I (in a colorectal tumor).
FT                                /FTId=VAR_006008.
FT   VARIANT     280    280       R -> K (in a breast tumor).
FT                                /FTId=VAR_006007.
FT   VARIANT     280    280       R -> T (in nasopharyngeal carcinoma).
FT                                /FTId=VAR_006009.
FT   VARIANT     281    281       D -> A (in a leukemia and a lymphoma).
FT                                /FTId=VAR_006010.
FT   VARIANT     281    281       D -> E (in many types of tumors).
FT                                /FTId=VAR_006011.
FT   VARIANT     281    281       D -> G (in many types of tumors).
FT                                /FTId=VAR_006012.
FT   VARIANT     281    281       D -> H (in HNSCC; same patient as
FT                                mutation Thr-278).
FT                                /FTId=VAR_006013.
FT   VARIANT     281    281       D -> V (in a colorectal tumor).
FT                                /FTId=VAR_006014.
FT   VARIANT     282    282       R -> L (in a breast tumor).
FT                                /FTId=VAR_006015.
FT   VARIANT     282    282       R -> W (in esophageal adenocarcinoma and
FT                                many types of tumors).
FT                                /FTId=VAR_006016.
FT   VARIANT     283    283       R -> C (in a colon tumor).
FT                                /FTId=VAR_006017.
FT   VARIANT     283    283       R -> G (in a lung tumor).
FT                                /FTId=VAR_006018.
FT   VARIANT     283    283       R -> H (in a colon tumor).
FT                                /FTId=VAR_006019.
FT   VARIANT     283    283       R -> P (in a breast and a lung tumor).
FT                                /FTId=VAR_006020.
FT   VARIANT     284    284       T -> A (in a colorectal tumor).
FT                                /FTId=VAR_006021.
FT   VARIANT     284    284       T -> P (in a lung tumor).
FT                                /FTId=VAR_006022.
FT   VARIANT     285    285       E -> K (in many types of tumors).
FT                                /FTId=VAR_006023.
FT   VARIANT     285    285       E -> Q (in an uterus tumor).
FT                                /FTId=VAR_006024.
FT   VARIANT     285    285       E -> V (in a liver tumor).
FT                                /FTId=VAR_006025.
FT   VARIANT     286    286       E -> A (in LFS).
FT                                /FTId=VAR_006026.
FT   VARIANT     286    286       E -> D (in a liver tumor).
FT                                /FTId=VAR_006027.
FT   VARIANT     286    286       E -> G (in tumors of colon, lung, head
FT                                and neck).
FT                                /FTId=VAR_006028.
FT   VARIANT     286    286       E -> K (in many types of tumors).
FT                                /FTId=VAR_006029.
FT   VARIANT     286    286       E -> Q (in esophageal adenocarcinoma).
FT                                /FTId=VAR_006030.
FT   VARIANT     292    292       K -> I (in LFS).
FT                                /FTId=VAR_015819.
FT   VARIANT     296    296       H -> P (in HNSCC).
FT                                /FTId=VAR_006031.
FT   VARIANT     300    300       P -> R (in a skin tumor).
FT                                /FTId=VAR_006032.
FT   VARIANT     301    301       P -> L (in a colon tumor).
FT                                /FTId=VAR_006033.
FT   VARIANT     302    302       G -> E (in a colon tumor).
FT                                /FTId=VAR_006034.
FT   VARIANT     302    302       G -> V (in a colon tumor).
FT                                /FTId=VAR_006035.
FT   VARIANT     306    306       R -> Q (in a sarcoma).
FT                                /FTId=VAR_006036.
FT   VARIANT     307    307       A -> T (in a breast tumor).
FT                                /FTId=VAR_006037.
FT   VARIANT     309    309       P -> S (in a colon tumor).
FT                                /FTId=VAR_006038.
FT   VARIANT     325    325       G -> V (in LFS).
FT                                /FTId=VAR_006039.
FT   VARIANT     334    334       G -> V (in a lung tumor).
FT                                /FTId=VAR_006040.
FT   VARIANT     337    337       R -> C (in LFS; nonclassical form; also
FT                                found in a liver tumor).
FT                                /FTId=VAR_006041.
FT   VARIANT     339    339       E -> K.
FT                                /FTId=VAR_022316.
FT   VARIANT     366    366       S -> A.
FT                                /FTId=VAR_022317.
FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by HIPK2
FT                                and acetylation of K-382 by CREBBP.
FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
FT   MUTAGEN     135    135       C->Y: Decreased E6-mediated binding to
FT                                E6-AP.
FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
FT   CONFLICT     76     76       A -> G (in Ref. 2; AAA59987).
FT   CONFLICT    155    155       T -> P (in Ref. 16).
FT   CONFLICT    254    254       I -> D (in Ref. 7; CAA42635).
FT   CONFLICT    262    262       G -> V (in Ref. 19).
FT   CONFLICT    282    282       R -> Q (in Ref. 18).
FT   STRAND      103    103
FT   HELIX       105    107
FT   TURN        108    108
FT   STRAND      110    112
FT   TURN        120    121
FT   STRAND      124    127
FT   TURN        128    131
FT   STRAND      132    135
FT   TURN        137    138
FT   STRAND      141    146
FT   TURN        153    154
FT   STRAND      156    163
FT   TURN        166    170
FT   HELIX       177    181
FT   TURN        191    192
FT   STRAND      195    197
FT   TURN        201    202
FT   STRAND      204    207
FT   TURN        209    211
FT   STRAND      214    219
FT   TURN        225    226
FT   STRAND      230    236
FT   TURN        240    241
FT   TURN        243    248
FT   STRAND      251    258
FT   TURN        260    261
FT   STRAND      264    274
FT   HELIX       278    286
FT   HELIX       335    354
FT   HELIX       376    378
FT   HELIX       379    384
FT   TURN        385    386
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
